Sensei Biotherapeutics (NASDAQ:FTH) Trading Up 10.5% – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price was up 10.5% during mid-day trading on Friday . The stock traded as high as $31.50 and last traded at $31.55. Approximately 263,397 shares traded hands during trading, an increase of 28% from the average daily volume of 205,415 shares. The stock had previously closed at $28.55.

Wall Street Analyst Weigh In

FTH has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective for the company. Oppenheimer assumed coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price for the company. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a research note on Thursday, May 28th. Finally, Wall Street Zen upgraded Sensei Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.90.

Sensei Biotherapeutics Stock Up 13.4%

The business has a 50 day simple moving average of $26.52. The company has a market capitalization of $836.85 million, a PE ratio of -0.23 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. As a group, equities analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Brian C. Stephenson purchased 9,391 shares of Sensei Biotherapeutics stock in a transaction on Wednesday, June 24th. The shares were purchased at an average cost of $26.13 per share, with a total value of $245,386.83. Following the transaction, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 49,494 shares of company stock worth $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the first quarter valued at $22,758,000. Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics during the 1st quarter worth about $4,188,000. Finally, Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.